Robert Bakin is a registered patent agent and contract specialist who focuses his practice on patent rights, technology issues, and business issues. He researches, reviews, and analyzes foreign and domestic patents and patent applications. He also prepares and reviews technology related contracts.

Dr. Bakin performs patent prior art searches, conducts patent due diligence (investor and company side), and analyzes complex freedom-to-operate issues. He has prepared and prosecuted foreign and domestic patent applications. He regularly researches various patent databases, reviews technical disclosures, and analyzes patent rights of clients and competitors throughout the world.

Dr. Bakin also prepares, reviews, and edits a wide range of contracts including master agreements, template agreements, subcontracts, and contract proposals. In this capacity, he also reviews and edits research plans, statements of work (SOW), technical project descriptions, and project deliverables.

He prepares contracts such as confidentiality and non-disclosure agreements (CDAs and NDAs), material transfer agreements (MTAs), patent licensing agreements, consulting agreements, sponsored research agreements (SRAs), clinical trial agreements (CTAs), general services agreements, and manufacturing agreements.

Dr. Bakin has experience working with a wide range of technologies, with an emphasis in the biotechnology and life sciences areas. He has worked with the following technologies: medical devices, diagnostics, infectious disease vaccines and therapeutics (bacterial and viral), immunology, pharmaceuticals (brand name, traditional generics, and protein based biogenerics), oncology, and genetics.

He received his Ph.D. in Microbiology from the University of Virginia publishing several papers on mammalian signal transduction and the molecular mechanisms of prostate cancer progression. As a post-doctoral fellow in the Department of Radiation Medicine at Georgetown University, Dr. Bakin researched novel molecular mechanisms responsible for enhancing cancer sensitivity to therapeutic doses of ionizing radiation.

Prior to graduate school, Dr. Bakin was a research assistant at the Johns Hopkins School of Medicine Department of Neuroscience. There, he co-authored several articles on the molecular mechanisms of mammalian olfaction, sperm motility and memory. While an undergraduate, he assisted in the evolutionary characterization of pathogenic strains of E. coli bacteria.

Prior Legal Experience

• Sterne, Kessler, Goldstein & Fox P.L.L.C.
• University of Virginia Patent Foundation, Licensing Department

Bar Admissions

• U. S. Patent and Trademark Office

Education

• Ph.D., The University of Virginia, Department of Microbiology, 2002
• B.S., The Pennsylvania State University, Biological Sciences, 1992

Prior Scientific Experience

• Georgetown University, The Lombardi Cancer Center, Department of
  Radiation Medicine
• University of Virginia, The University of Virginia Cancer Center
• Johns Hopkins University, Department of Neuroscience
• Pennsylvania State University, Department of Evolutionary Genetics

Industry Collaborations

• Collaboration with Pfizer Inc. during Phase-1 pre-clinical drug trials using a third-generation small molecule cancer therapeutic
• Collaboration with AstraZeneca PLC for therapeutic synergisms using a cancer therapeutic

Research Grants and Awards based on Dr. Bakin's Research

• National Institutes of Health Research Project Grant (NIH RO1): NIH grant #1R01CA105402-01 (2004-2009)
• Postdoctoral Traineeship Grant: Department of the Army Prostate Cancer Research Program (2004-2006)
• Scholars-in-Training Travel Award: Radiation Research Society (2004)
• Prostate Cancer Foundation Grant: PCFG grant (2000-2001)

Invited Speaker

• American Conference Institute's Conference on Biosimilars, New York, New York (2011)
• United States Food & Drug Administration, Silver Spring, Maryland (Hearing on the Approval Pathway for Biosimilar and Interchangeable Biological Products) (2010)
• Radiation Research Society National Meeting, St. Louis, Missouri (2004)
• University of Virginia Graduate Bioscience Society Meeting, Charlottesville,
  Virginia (2002)
• American Association for Cancer Research (AACR) National Meeting, New Orleans, Louisiana (2001)
• Oncogene National Meeting, Hood College, Maryland (2001)

Professional and Civic Activities

• Member, American Association for Cancer Research
• Member, American Society for Cell Biology
• Member, the Radiation Research Society
• Volunteer, U.S. Botanic Gardens

Publications

• Bakin RE., and Rhee B., The United States Patient Protection and Affordable Care Act of 2010: How Advances in Bioanalytics Might Cloud FDA Approval of Follow-On Biologics, Technology & Business Law Advisors, Winter 2010-2011.
• Bakin RE., and Rhee B., The United States Patient Protection and Affordable Care Act of 2010: Clarifying “Exclusivity”, “Evergreening” and “Related Entities” Terminology, Technology & Business Law Advisors, Fall 2010.
• Bakin RE., and Rhee B., United States FDA Approval Of Generic Lovenox^®: A First Glimpse At Follow-On Biologic Sameness, Technology & Business Law Advisors, Summer 2010.
• Bakin RE., and Rhee B., The United States Patient Protection and Affordable Care Act of 2010: Perils of Mandatory Pre-Litigation Disclosure of Confidential Information, Technology & Business Law Advisors, Summer 2010.
• Nevrivy DJ and Bakin RE., “China Gets Serious About Biotech”, September 2, 2009.
• Bakin RE., and Jung MO., “HDAC2 Cytoplasmic Sequestration Potentiates Keratinocyte Terminal Differentiation”, The Open Cell Development & Biology Journal, 1, 1-8 (2007).
• Bakin RE., and Jung MO., “Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis”, Journal of Biological Chemistry, 279(49):51218-25 (2004).
• Bakin RE., Sikes RA, Gioeli D., Weber MJ., “Constitutive activation of the Ras/Mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells”, Cancer Research, 63(8):1981-9 (2003).
• Bakin RE., Gioeli D, Bissonette EA., Weber MJ., “Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells”, Cancer Research, 63(8):1975-1980 (2003).
• Matsuzaki O., Bakin RE., Cai X., Menco BP., Ronnett GV., “Localization of the olfactory cyclic nucleotide-gated channel subunit 1 in normal, embryonic and regenerating olfactory epithelium”. Neuroscience, 94(1): 131-40 (1999).
• Walensky LD., Ruat M., Bakin RE., Blackshaw S., Ronnett GV., Snyder SH., “Two novel odorant receptor families expressed in spermatids undergo 5’-splicing”. Journal of Biological Chemistry, 273(16): 9378-87, 1998 Apr 17.
• Bradley J., Zhang Y., Bakin R., Lester HA., Ronnett GV., Zinn K., “Functional expression of the heteromeric “olfactory” cyclic nucleotide-gated channel in the hippocampus: a potential effector of synaptic plasticity in brain neurons”. Journal of Neuroscience, 17(6): 1993-2005, 1997 Mar 15.